Project Grant R01EY037352
- The National Eye Institute awarded The Johns Hopkins University $624,689 under the Vision Research program (CFDA 93.867) on September 1, 2026, to develop machine learning-driven peptide engineering for sustained intraocular pressure lowering in glaucoma treatment. The research applies artificial intelligence methodology adapted from the super learning approach to engineer multifunctional peptides that bind to melanin, enter cells efficiently, and exhibit low cytotoxicity. High-throughput...
- The National Eye Institute of the Department of Health and Human Services awarded $571,206 to the University of Maryland, Baltimore on May 1, 2026, under the Vision Research program (CFDA 93.867) to develop, refine, and validate sensitive and robust adaptive optics-optical coherence tomography (AO-OCT) biomarkers for glaucoma detection and progression monitoring. The project addresses the need for earlier detection of glaucoma progression and mechanistically relevant biomarkers to support...
- The National Eye Institute awarded The Washington University $427,625 under the Vision Research program (CFDA 93.867) on April 1, 2026, to develop novel statistical methodologies for detecting visual field progression in primary open-angle glaucoma using data from the Ocular Hypertension Treatment Study. The project delivers three core products: a change-point model for mean deviation progression that integrates longitudinal measures with time-to-detectable-change to identify early disease...
- Federal Grant Award Summary Johns Hopkins University received a $621,250 Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) on September 15, 2025, with a completion date of August 31, 2027. The project, titled "Gaze-Contingent AI-Enabled Low Vision Assistive Technology (GALVAT)," will develop smart assistive technology designed to address information overload challenges in vision loss rehabilitation devices. The research...
- The National Eye Institute awarded The Schepens Eye Research Institute $858,394 on August 1, 2026, under the Vision Research program (CFDA 93.867) to develop multimodal foundation models for eye disease screening and prognosis. The research develops a vision-language foundation model trained on pairs of retinal images and clinical notes to enable downstream supervised models for detection and progression prediction of age-related macular degeneration, diabetic retinopathy, and glaucoma. The...
- The National Eye Institute awarded The Johns Hopkins University $698,999 on July 1, 2026, under the Vision Research program (CFDA 93.867) to conduct research on mechanisms of functional retinal engraftment by transplanted retinal ganglion cells for optic neuropathies including glaucoma. The project addresses the death of retinal ganglion cells (RGCs), which transmit visual information from the eye to the brain. While existing treatments slow vision loss in some progressive optic neuropathies, no...
- The National Eye Institute awarded the Regents of the University of Minnesota $764,310 on July 1, 2026, under the Vision Research program (CFDA 93.867) to develop robust multimodal artificial intelligence models for primary open-angle glaucoma prognosis. The recipient will develop deep learning models that integrate longitudinal data from fundus images, optical coherence tomography, visual fields, and structured clinical variables to estimate individual likelihood of developing primary...
- The National Eye Institute, part of the Department of Health and Human Services National Institutes of Health, awarded The Johns Hopkins University $148,062 on January 23, 2026, under the Vision Research program (CFDA 93.867) to conduct research on pathway-specific eligibility traces in reinforced cortical learning. The recipient will use electrophysiology to test whether eligibility traces—transient synaptic tags that enable learning through delayed reinforcement—are restricted to specific...
- The National Eye Institute awarded the University of Alabama at Birmingham $636,862 on April 1, 2026, under the Vision Research program (CFDA 93.867) to develop and validate mechanical, vascular, and morphometric biomarkers of eye-specific susceptibility to glaucoma onset and progression. The recipient will perform longitudinal optical coherence tomography imaging to quantify optic nerve head mechanical deformations and vascular perfusion in vivo in an animal model of unilateral glaucoma...
- The National Eye Institute awarded The Johns Hopkins University $427,504 on July 1, 2026, under the Vision Research program (CFDA 93.867) to develop BLAB-SEQ, a non-toxic, transgene-based method that combines fluorescent birth dating with single-cell RNA sequencing to determine birth dates and transcriptomic profiles of neuronal subtypes in human organoids. The project will integrate birth-labeled sequencing with multiomics analysis to directly link neuronal birth timing and fate...
The National Eye Institute awarded The Johns Hopkins University $776,269 on August 1, 2026, under the Vision Research program (CFDA 93.867) to develop and externally validate critical elements of a clinical decision support system (CDSS) that optimizes treatment selection for glaucoma patients experiencing rapid visual field deterioration. The project addresses a treatment gap: randomized controlled trials demonstrate that non-medical interventions (surgery or laser trabeculoplasty) produce less visual field loss than medical treatment alone, yet only 42 percent of rapid progressors receive these interventions. The investigators previously developed high-performing artificial intelligence models to predict rapid progression and recommend aggressive treatment, but found that clinicians under-relied on AI recommendations, with clinician performance falling below AI-alone performance. The award funds development of two critical CDSS elements. First, an underlying causal model will enable clinicians to forecast the personalized effects of all common treatments for individual glaucoma patients. Second, the team will assess which user interface interpretability features optimize the clinician-CDSS team's ability to select treatment that minimizes visual field loss likelihood. Development leverages a large longitudinal multimodal dataset of over 1.3 million glaucoma patient encounters. Work is performed in Baltimore, Maryland, with a performance period ending April 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $776.3k | 7/31/26 |